Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
Trackers› Clinical trials› Daegu
Clinical trial register · South Korea

Clinical Trials in Daegu, 2026

Every study on the ClinicalTrials.gov registry that lists a site in South Korea and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 3365 matching records held by the registry are in this view. Synced 11 Oct 2026, 03:17 UTC
3365
Studies in scope
all four open statuses
1831
Recruiting now
open to new participants
500
Lead sponsors
across recruiting studies
Top sites
Seoul 87 Busan 16 Daegu 13 Incheon 13 Suwon 13
Narrow the registerReset
Recruitment status
Phase
Site location
Seoul87 Busan16 Daegu13 Incheon13 Suwon13
All 41 locations
Target enrolment
to

Trials with a site in Daegu

13 of 3365 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in South Korea
Start
Recruiting
Novartis Pharmaceuticals
Phase 3
5,700
Daegu, Wŏnju, Bundang Gu, Suwon, Incheon, Seoul, Busan, Gwangju
2026-05-11
Recruiting
Remibrutinib Open Label Roll-over Post-trial Access Protocol
NCT07456891Indication of the Parent Protocol
Novartis Pharmaceuticals
Phase 3
648
Daegu, Hwaseong-si, Suwon, Dongjak Gu, Seoul, Gwangju, Incheon
2026-04-16
Active, closed
Novartis Pharmaceuticals
Phase 3
146
Daegu, Gwangju, Seoul
2024-07-31
Recruiting
Novartis Pharmaceuticals
Observational
44
Daegu, Suwon, Incheon, Seoul, Busan, Daejeon, Jeollanam
2023-06-12
Active, closed
Novartis Pharmaceuticals
Phase 3
696
Daegu, Hwaseong-si, Suwon, Incheon, Seoul, Gwangju
2022-12-09
Recruiting
Novartis Pharmaceuticals
Observational
900
Cheonan Si, Daegu, Goyang-si, Suwon, Gyeonggi-do, Seoul, Busan, Daejeon
2022-06-29
Active, closed
Novartis Pharmaceuticals
Observational
670
Daegu, Kangwon Do, Wŏnju, Goyang-si, Guri-si, Jinju, Jeonju, Iksan Si
2022-05-09
Active, closed
Novartis Pharmaceuticals
Observational
683
Daegu, Wŏnju, Bucheon-si, Bundang Gu, Goyang-si, Yangsan, Jeonju, Suncheon
2022-05-09
Active, closed
Novartis Pharmaceuticals
Phase 3
17,004
Daegu, Wŏnju, Bundang Gu, Jinju, Yangsan, Incheon, Seoul, Cheongju-si
2021-11-23
Recruiting
Regulatory Post-Marketing Surveillance Study for Brolucizumab
NCT04985487Neovascular Age-related Macular Degeneration
Novartis Pharmaceuticals
Observational
3,000
Daegu, Goyang-si, Guri-si, Suwon, Iksan Si, Daejeon, Busan, Gwangju
2021-08-18
Active, closed
Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2)
NCT04603495Myelofibrosis, Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
Novartis Pharmaceuticals
Phase 3
430
Jinju, Busan, Daegu, Gyeonggi-do, Incheon, Jeonju, Seoul, Ulsan
2021-04-09
Recruiting
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
NCT04104776Advanced Solid Tumor, Diffuse Large B Cell Lymphoma, Lymphoma, T-Cell, Mesothelioma, Malignant
Novartis Pharmaceuticals
Phase 1/2
300
Daegu, Goyang-si, Incheon, Seoul
2019-09-18
Recruiting
Novartis Pharmaceuticals
Observational
700
Daegu, Seongnam-si, Seoul, Yangsan, Yongin-si
2018-09-25
Rows per page Showing 1–13 of 13
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a South Korean investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 11 October 2026. https://priyalifescience.com/clinical-trials-south-korea/city/daegu

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in South Korea and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 3,365 studies in total at the last sync on 11 Oct 2026, 03:17 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 13 of those studies with a site in Daegu that also match the filters currently applied.

How many clinical trials are recruiting in Daegu?

7 of the 13 studies on this page are recruiting new participants as of the 11 Oct 2026, 03:17 UTC sync. A further 0 have not yet opened recruitment, 6 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Daegu), 13 studies
PhaseStudiesRecruitingShare
Observational6446.2%
Phase 36246.2%
Phase 1/2117.7%

Most active sponsors

Lead sponsors with the most studies (Daegu)
Lead sponsorStudiesRecruiting
Novartis Pharmaceuticals137
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.